Vercise DBS instruction recall: why IFU corrections matter to trial teams
Health Canada's Type II recall of Vercise clinician programmer instructions is narrow, but it shows how a labelling correction can ripple into protocols, training and site files.
What happened
On 13 November 2026 Health Canada listed a Type II recall in which Boston Scientific is correcting the instructions for use (IFU) for Vercise Clinician Programmers, part of the Vercise deep brain stimulation (DBS) system. The correction covers two topics: how often the implantable pulse generator (IPG) needs recharging, and the estimates given for battery longevity.
The record describes a correction to written instructions. It does not describe a hardware fault, a software defect or a device removal. It also does not say what the revised intervals or estimates are, how many units are affected, whether any patient harm was reported, or whether regulators outside Canada have taken parallel action. Those details sit in the notice and the manufacturer's communication, not in the summary.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Sources this analysis is based on
- Boston Scientific updates Vercise DBS Clinician Programmer instructions on battery recharge and longevity estimates Health Canada · Fri 13 Nov 2026
- Bluejay completes SYMON-II enrolment for Symphony IL-6 sepsis test, eyes 510(k) filing in H1 2027 Bluejay Diagnostics, Inc. · Fri 13 Nov 2026
- TuHURA wins FDA IND clearance for VISTA antibody TBS-2025 in relapsed AML TuHURA Biosciences, Inc./NV · Fri 13 Nov 2026
- Oncolytics and Coherus agree toripalimab supply for pelareorep anal cancer study Oncolytics Biotech Inc · Thu 12 Nov 2026
- Slovakia's ŠÚKL issues guideline on notifying intent to vaccinate in pharmacies ŠÚKL · Thu 12 Nov 2026
- FDA Issues Draft Guidance on Early-Phase IND Protocols for Solid Tumour Trials FDA · Thu 12 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
FTC's bid to block Covetrus-MWI puts veterinary distribution, and PV information flow, in focus
The US suit against a $3.5bn merger of the two largest vet distributors is an antitrust case, but animal-health PV teams should check how safety information moves through the channel.
Denmark's Voltabak shortage to mid-May 2027 shows how fragile single-source supply is
DKMA's updated notice on Laboratoires Thea's diclofenac eye drops, with the Methergin withdrawal and estradiol patch notices, shows how Denmark manages supply failures.
Illinois Medicaid charges show no pharma link, but the compliance signal is worth reading
Illinois's attorney general has charged three people in two Medicaid fraud cases, with no stated link to medicines. For quality and compliance teams, the context around it matters more than the case.